Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33 CHF | +2.48% | +1.54% | -33.87% |
Apr. 23 | Xlife Sciences Posts Higher FY23 Profit; Revenue Falls | MT |
Feb. 29 | Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 800K 886K | Sales 2025 * | - | Capitalization | 188M 208M |
---|---|---|---|---|---|
Net income 2024 * | -4M -4.43M | Net income 2025 * | - | EV / Sales 2024 * | 317 x |
Net Debt 2024 * | 65.2M 72.22M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-50
x | P/E ratio 2025 * |
-
| Employees | 17 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 49.77% |
1 day | +2.48% | ||
1 week | +1.54% | ||
1 month | +3.12% | ||
3 months | -19.71% | ||
6 months | -15.60% | ||
Current year | -33.87% |
Managers | Title | Age | Since |
---|---|---|---|
Oliver Baumann
CEO | Chief Executive Officer | - | 19-06-30 |
Carl von Halem
DFI | Director of Finance/CFO | - | 21-11-30 |
Alexander Zink
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Christian Faber
CMP | Compliance Officer | - | 19-09-11 |
Mark Müller
BRD | Director/Board Member | - | 18-10-24 |
Oliver Baumann
CEO | Chief Executive Officer | - | 19-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 33 | +2.48% | 4,414 |
24-05-30 | 32.2 | -2.42% | 4,592 |
24-05-29 | 33 | -2.37% | 3,033 |
24-05-28 | 33.8 | +2.11% | 2,076 |
24-05-27 | 33.1 | +1.85% | 2,383 |
Delayed Quote Swiss Exchange, May 31, 2024 at 11:30 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-33.87% | 208M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- XLS Stock